PDL BioPharma Elects Barry Selick to Its Board of Directors
INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors.
"Barry's experience as a seasoned biotechnology executive and his extensiv...
PDL BioPharma Announces Second Quarter 2009 Financial Results
INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today reported financial results for the second quarter ended June 30, 2009.
Total revenues from continuing operations for the second quarter of 2009 were $125.9 million,...
PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
INCLINE VILLAGE, Nev., July 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that the company will hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter of 200...
DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Christopher P. Schnittker, CPA as its new Vice President of Administration and Controller. In th...
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
GAI-122, an investigational injectable nanoemulsion formulated with
AlphaRx's proprietary drug delivery technology, providing significant
neuro-protection in multiple in vitro and in vivo studies which suggest
that this injectable nanoemulsion formulation has the potential to
Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
AURORA, Ontario, June 23 /PRNewswire-FirstCall/ -- Helix BioPharma
Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF. Investors can find real-time quotes, disclosure and financial informati...
AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
GAI-122, an investigational injectable nano-emulsion formulated with
AlphaRx's proprietary drug delivery technology, provides significant
neuroprotection in animal behavioral models. Gaia BioPharma
initiate a clinical development program to further study GAI-122 for an
PDL BioPharma Announces Record Date for October 1 Dividend Payment
INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009. The Company previously announced that it would pay t...
The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate
CLINTON, N.J., May 27 /PRNewswire/ -- The Sage Group, a privately held international health care consulting group, announced today that HemispherX Biopharma
has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental ...
PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer
- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule -
INCLINE VILLAGE, Nev., April 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that its board of directors has appointed Karen J. Wilson as vice president of fin...
Biopharma in Medical Technology
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--
--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--
RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...
Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
SUNNYVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharmacyclics (Nasdaq: PCYC ) announced today the close of a financing in connection with an investment by the principals of Pacific Biopharma
Group, Ltd. (PBG), located in San Bruno California and Taizhou, Jiangsu Province, People's Republi...
Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and
manufacturing organization for sterile filling, announced it has retained a
strategic financial partner to help it expand operations to meet the global
biopharma demand for Isogen's services.
Isogen has previously anno...
Isogen Launches Major New Facility to Address Global Biopharma Demand
NEWARK, Del., Nov. 19 /PRNewswire/ -- Isogen, a contract development and
manufacturing organization for sterile filling, today announced the first
phase launch of its contract facility in Delaware. Isogen was founded to
specifically address the process, facility and capacity problems commonly
CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma,
Inc., a clinical stage company developing and commercializing innovative
treatments for diseases of the central nervous system, today announced that
it has initiated a Phase II clinical trial for its lead product candidate...
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
- State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties - - Results Support Initiation of Phase II Clinical Trials -
RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire/ -- CeNeRx BioPharma,
Inc., a clinical stage company developing ...
Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus
BioPharma, Inc. (OTC: CBIA), a biotechnology company developing
pharmaceutical products and assay methods for patients suffering from
infectious disease, radiation sickness, cancer and addiction, today
announced the signing of ...
CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
- Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies -
RESEARCH TRIANGLE PARK, N.C., Jan. 16 /PRNewswire/ -- CeNeRx BioPharma,
Inc., a clinical stage company developing and commercializing innovative
treatments for diseases of the...
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at
the Fourth International Conference on Tumor Microenvironment in
- Helix BioPharma
Corp. (TSX: HBP /Frankfurt: WKN
AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research
at Helix BioPharma
Corp., a developer of novel cancer therapeutics,
will be presenting a scientific poster at the Fourth International
Conference on Tumor Microenvi...
Biopharma in Biological News
Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
... and Robert Pierce, currently head of anatomic pathology at Schering-Plough biopharma
and formerly of the University of Rochester Medical Center, are collaborati...
OHSU turns innovations into commercial opportunities at record pace
...formation about Molecular MD, go to http://www.molecularmd.com ]
which was spun off by Virogenomics Inc., an earlier OHSU startup -- was c...hnology and pharmaceutical companies in focusing on infectious diseases. ID biopharma
will function as the commercialization accelerator for the Oregon Translati...
Intelligent materials to regenerate bone tissue
...nerate in such a way that it carries out similar functions as in its natural state. From Spain the Institute of Biomechanics of Valencia and Progénika biopharma
S.A. are also participating.
In the case of substantial deterioration of the bone, it may be necessary for the implant to provide both functional...
Ocean virus identified in human blood samples
...ys available to test for Vesivirus infection or antibodies, researchers say, that have been developed at OSU and licensed to private industry.
has investigated their proprietary NeuGene antisense as an anti-Vesiviral treatment, and is currently conducting further research and development," sa...
Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
... the United States and Europe. The CDC classifies ricin as a "Category B" biological agent, which means it is "relatively easy to disseminate."
has received an exclusive license for RiVax and is developing large scale manufacturing processes. DOR officials hope to produce a large stockpile for...
Biopharma in Biological Technology
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...
PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednes...
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral...
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma
Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of can...
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning...
KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreemen...
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma
Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma
Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Ass...
Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian
biopharmaceutical company Lytix Biopharma
and Korean company KAEL-GemVax
today announced the signing of a collaborative agreement to test lead
compounds LTX-315 and GV1001 as a combination therapy for the treatment of
Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
FORT WORTH, Texas, June 16 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.OB), announced today that it has reached an agreement in principle to acquire BioPharma
Management Technologies, Inc., a privately held biotechnology company with a pl...
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma
Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009.
THIRD QUARTER HIGHLIGHTS AND P...
Biopharma in Biological Products
ELISA Biopharma from Tecan
Description: Tecan has 20 years of expertise in the field of Enzyme-Linked Immunosorbent Assays (ELISA), and still offers the most powerful systems on the market. Freedom EVO easily manages up to 40 000 in-microplate tests requiring incubation and washing steps. The integration of different modules (such as w...